Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11393685 | 0.91 | ALPL (0.37) | ALPLHPGDSMN1; SMN2MAPK1CYP3A4 | |
| SCHEMBL6767875 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TP53HTT | |
| SCHEMBL1220108 | 0.76 | HSD17B10 (0.42) | ALPLHPGDMAPK1CYP3A4CYP2C9 | |
| SCHEMBL6773600 | 0.76 | ALDH1A1 (0.55) | SMN1; SMN2HSD17B10KMT2AALDH1A1KDM4E | |
| SCHEMBL5417695 | 0.75 | AURKA (0.41) | ALPLHPGDMAPK1CYP3A4CYP2C9 | |
| SCHEMBL6779126 | 0.75 | RXFP1 (0.48) | ALPLSMN1; SMN2MAPK1KMT2AALDH1A1 | |
| SCHEMBL6891078 | 0.75 | LMNA (0.55) | SMN1; SMN2TP53LMNA | |
| SCHEMBL7663410 | 0.75 | HSD17B10 (0.41) | ALPLHPGDMAPK1CYP3A4CYP2C9 | |
| SCHEMBL6948324 | 0.74 | KDM4E (0.39) | HPGDHSD17B10KMT2AALDH1A1KDM4E | |
| SCHEMBL6770340 | 0.74 | BUB1 (0.40) | ALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | disclosed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | disclosed |
| EP-1030838-B1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6489347-B1 | NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-03 | — | — | US | disclosed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| US-6262272-B1 | REACTING FURAN CARBOXYLIC ACID DERIVATIVE WITH ACID CHLORIDE OR ACID ANHYDRIDE IN INERT SOLVENT CONTAINING ACID RECEPTOR; ADDING AROMATIC AMINE COMPOUND TO FORM PYRROLE CARBOXAMIDE COMPOUND | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
| EP-1030838-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999025684-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | ALPL 2411/4885HPGD 1539/4885SMN1; SMN2 1796/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | ALPL 2455/4885HPGD 1116/4885SMN1; SMN2 990/4885 |
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | ALPL 2825/4885HPGD 1363/4885SMN1; SMN2 3833/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | ALPL 3570/4885HPGD 1673/4885SMN1; SMN2 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.